Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2026-01-11 @ 9:11 PM
Study NCT ID:
NCT03278405
Status:
COMPLETED
Last Update Posted:
2020-03-18
First Post:
2017-08-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Avelumab in G3 NEC
Sponsor:
Sunnybrook Health Sciences Centre
Organization:
Study Overview
Official Title:
A Pilot Study of Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated Grade 3 Neuroendocrine Carcinomas
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NET-001
Brief Summary:
This is a single-center, single-arm, open-label, pilot trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 3, poorly-differentiated neuroendocrine.carcinoma.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?: